Inspira Technologies OXY B.H.N. (NASDAQ:IINN) & Waters (NYSE:WAT) Head to Head Comparison

Inspira Technologies OXY B.H.N. (NASDAQ:IINN) and Waters (NYSE:WAT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Volatility and Risk

Inspira Technologies OXY B.H.N. has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, Waters has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Inspira Technologies OXY B.H.N. and Waters, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspira Technologies OXY B.H.N.	1	0	0	0	1.00
Waters	0	8	9	3	2.75

Waters has a consensus target price of $396.00, indicating a potential upside of 5.05%. Given Waters’ stronger consensus rating and higher possible upside, analysts plainly believe Waters is more favorable than Inspira Technologies OXY B.H.N..

Profitability

This table compares Inspira Technologies OXY B.H.N. and Waters’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A
Waters	11.91%	15.60%	8.90%

Insider and Institutional Ownership

12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. Comparatively, 94.0% of Waters shares are held by institutional investors. 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Comparatively, 0.3% of Waters shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Inspira Technologies OXY B.H.N. and Waters”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspira Technologies OXY B.H.N.	$289,000.00	381.88	-$13.22 million	N/A	N/A
Waters	$3.17 billion	11.69	$642.63 million	$7.87	47.90

Waters has higher revenue and earnings than Inspira Technologies OXY B.H.N..

Summary

Waters beats Inspira Technologies OXY B.H.N. on 10 of the 13 factors compared between the two stocks.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.